Nathan H. Fowler, MD - A Better Blend for Follicular Lymphoma: How Targeted, Epigenetic, and Immune Therapies Are Changing Patient Care

PeerView Oncology & Hematology CME/CNE/CPE Audio Podcast

Go online to PeerView.com/FJR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Prepare for this CME-certified “Clinical Consults” video, where expert faculty will guide you through the challenges and opportunities inherent in the management of R/R follicular lymphoma. Throughout, the experts will provide guidance on how a “better blend” of therapeutics can be selected and sequenced to provide maximum benefit for patients, while also providing evidence that supports the continued integration of novel antibodies, targeted and epigenetic agents, and CAR-T cell therapies into patient management. Upon completion of this CE activity, participants will be able to: Cite evidence supporting a therapeutic role for innovative targeted, epigenetic, antibody-based, and CAR-T options in the sequential management of relapsed/refractory follicular lymphoma (R/R FL), Recommend sequential treatment strategies for R/R FL using chemo-sparing regimens, targeted agents, novel antibodies, epigenetic modifiers, and cellular therapy, Manage the unique spectrum of adverse events associated with novel therapeutics for patients with R/R FL.